Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71610-031

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 250mg (71610 031 60)

Label for Divalproex Sodium Delayed-Release Tablets, 250 mg, containing 90 tablets. The label includes storage instructions and manufacturer information, noting repackage by Aphena Pharma Solutions - Tennessee, LLC, and original manufacture by Upsher-Smith Laboratories in Minneapolis, MN. The product is for oral use and requires a prescription.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Divalproex 01)

Chemical structure of divalproex sodium depicted as a molecular diagram showing its bonding arrangement, including sodium ion (Na+), and organic substituents with carbon, hydrogen, and oxygen atoms.*

FDA Label Image

Figure 1 (Divalproex 02)

A bar chart comparing percentage values between placebo (PBO) and Divalproex Sodium (DVPX) across two studies. Study 1 uses the YMRS scale with 26% for PBO and 60% for DVPX. Study 2 uses the MRS scale with 29% for PBO and 58% for DVPX. The y-axis shows percentages from 0% to 70%.*

FDA Label Image

Figure 2 (Divalproex 03)

A cumulative response curve graph showing the percentage of patients on the x-axis and percentage reduction in CPS (Clinical Parameter Score) rate on the y-axis. It compares Divalproex sodium delayed-release tablets USP (solid line) versus placebo (dashed line), indicating improvement or worsening relative to no change at zero percent reduction.*

FDA Label Image

Figure 3 (Divalproex 04)

A cumulative distribution plot showing the percentage reduction in CPS rate among patients at varying doses. The x-axis represents the percentage of patients, and the y-axis indicates the percentage reduction in CPS rate, ranging from -100% (worsening) to 100% (improvement). Two lines compare outcomes for high dose (solid line) and low dose (dashed line) groups.*

FDA Label Image

Figure 4 (Divalproex 05)

A bar chart comparing results between placebo and divalproex sodium in two studies labeled Study 1 and Study 2. Study 1 shows higher values for placebo than divalproex sodium, and Study 2 also shows higher values for placebo compared to divalproex sodium, with values represented on the vertical axis ranging from 0 to 6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.